FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alison Stopeck

Research Profile

Disorders

Procedures

Chemicals & Drugs

Devices

Gene Transfer Techniques

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Alison T Stopeck; Ze Cong; Roger Dansey; David Henry; Yi Qian; Jorge Arellano
Authors' response to letter to the editor.
Allan Lipton; Pablo Maroto; Michael Rader; Gary E Richardson; Fred Saad; Salvatore Siena; Alison T Stopeck; Maria Viniegra; Denise A Yardley; Philippe Beuzeboc; Boris Bilynskyy; Ada Braun; Janet E Brown; Veena Charu; Michael Clemens; Karim Fizazi; David H Henry; Chunlei Ke; Susie Jun
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
M Iannone; L Pennick; H Cui; M Gilbert; Angela K. Tom; K Weihs; Alison T Stopeck
Prevalence of depression in adults with haemophilia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alison Stopeck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alison T Stopeck; Ze Cong; Roger Dansey; David Henry; Yi Qian; Jorge Arellano
Authors' response to letter to the editor.
Journal of medical economics 2013;16(2):262-3.
2012: Allan Lipton; Pablo Maroto; Michael Rader; Gary E Richardson; Fred Saad; Salvatore Siena; Alison T Stopeck; Maria Viniegra; Denise A Yardley; Philippe Beuzeboc; Boris Bilynskyy; Ada Braun; Janet E Brown; Veena Charu; Michael Clemens; Karim Fizazi; David H Henry; Chunlei Ke; Susie Jun
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
European journal of cancer (Oxford, England : 1990) 2012;48(16):3082-92.
2012: M Iannone; L Pennick; H Cui; M Gilbert; Angela K. Tom; K Weihs; Alison T Stopeck
Prevalence of depression in adults with haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia 2012;18(6):868-74.
2012: Alison T Stopeck; Hong Yuen Wong; Sara E Barnato; Ursa Brown-Glaberman; William J Gradishar; Clifford A Hudis; Ben Ho Park; Hope S Rugo
The role of targeted therapy and biomarkers in breast cancer treatment.
Clinical & experimental metastasis 2012;29(7):807-19.
2012: Miguel Martin; Alexander H G Paterson; Diana Ritchie; Günther G Steger; Alison T Stopeck; Charles Vogel; Richard Bell; Hugues Bourgeois; Adam Brufsky; Karen Chung; Roger Dansey; Ingo Diel; Alexandru Eniu; Lesley Fallowfield; Michelle Fan; Yasuhiro Fujiwara; Jacek Jassem; Qi Jiang; Ada Braun
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4841-9.
2012: Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; Brent Farnsworth; Richard I Fisher; Martha J Glenn; Maria Iannone; Michael LeBlanc; Thomas P Miller
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Blood 2012;120(6):1210-7.
2012: Abhinav K Jha; Matthew A Kupinski; Jeffrey J Rodríguez; Renu M Stephen; Alison T Stopeck
Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard.
Physics in medicine and biology 2012;57(13):4425-46.
2012: Hope S Rugo; Janet Scott; Alison T Stopeck; A Jo Chien; Sandra X Franco; Alexa Glencer; Clifford Hudis; Soumi Lahiri; Ben Nulsen; John W Park; Michael C Arbushites; Maura Dickler
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Breast cancer research and treatment 2012;134(1):13-20.
2012: Ursa Brown-Glaberman; Alison T Stopeck
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
Biologics : targets & therapy 2012;6():89-99.
2012: Alison T Stopeck; Ze Cong; Mark Danese; Roger Dansey; Marc Halperin; David Henry; Yi Qian; Michael Rader; Karen Chung
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Journal of medical economics 2012;15(4):712-23.
2011: David E Gerber; Lee S Rosen; Joseph S Shan; Alison T Stopeck; Philip E Thorpe; Lucas Wong; Nuhad K Ibrahim
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6888-96.
2011: Julie R Gralow; Allan Lipton; Alison T Stopeck
How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(26):3591-2; author reply 3592-3.
2011: Hope S Rugo; Alison T Stopeck; Shailendra Verma; Angel H Bair; Paul Bycott; Stephen Chan; Anil A Joy; Sinil Kim; Katherine F Liau; Anna Lluch; Brad Rosbrook; Denis Soulieres
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(18):2459-65.
2010: Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(35):5132-9.
2010: Pavani Chalasani; Leona Downey; Alison T Stopeck
Caring for the breast cancer survivor: a guide for primary care physicians.
The American journal of medicine 2010;123(6):489-95.
2010: Cynthia A Thomson; Alison T Stopeck; Jennifer W Bea; Ellen C Cussler; Emily Nardi; Georgette Frey; Patricia A Thompson
Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets.
Nutrition and cancer 2010;62(8):1142-52.
2010: Patricia A Thompson; Chiu-Hsieh Hsu; Sylvan Green; Alison T Stopeck; Karen Johnson; David S Alberts; H-H Sherry Chow
Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
Cancer prevention research (Philadelphia, Pa.) 2010;3(1):101-7.
2009: Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael LeBlanc; Richard I Fisher; Thomas P Miller
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
Leukemia & lymphoma 2009;50(5):728-35.
2007: Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford Hudis
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Leona Downey; Robert Livingston; Alison T Stopeck
Diagnosing and treating breast cancer in elderly women: a call for improved understanding.
Journal of the American Geriatrics Society 2007;55(10):1636-44.
2007: Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
Blood 2007;109(12):5136-42.
2006: G Thomas Budd; Massimo Cristofanilli; Matthew J Ellis; Alison T Stopeck; Ernest C Borden; M Craig Miller; Jeri Matera; Madeline Repollet; Gerald V Doyle; Leon W M M Terstappen; Daniel F Hayes
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6403-9.
2006: Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison T Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W M M Terstappen
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4218-24.
2005: Alison T Stopeck
Women's health: the struggle to restore hormonal balance.
The American journal of medicine 2005;118(11):1181-2.
2005: David S Alberts; John D Potter; Maria Elena Martinez; Lisa M Hess; Alison T Stopeck; Peter Lance
What happened to the coxibs on the way to the cardiologist?
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(3):555-6.
2005: Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Matthew J Ellis; Alison T Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1420-30.
2004: Rebecca J Theilmann; Rebecca Borders; Theodore P Trouard; Guowei Xia; Eric K Outwater; James Ranger-Moore; Robert J Gillies; Alison T Stopeck
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy.
Neoplasia (New York, N.Y.) 2004;6(6):831-7.
2004: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison T Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
The New England journal of medicine 2004;351(8):781-91.
2004: Anne-Marie O'Farrell; Helene A Yuen; Beverly D Smolich; Alison L Hannah; Sharianne G Louie; Weiru Hong; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Judith E Karp; Maher Albitar; Julie M Cherrington; Francis Giles
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: Maurizio Zangari; Elias Anaissie; Alison T Stopeck; Alyssa Morimoto; Nguyen Tan; Jeffrey E Lancet; Maureen Cooper; Alison L Hannah; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb; Julie M Cherrington; Maher Albitar; Francis Giles
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Francis Giles; Maureen A Cooper; Lewis Silverman; Judith E Karp; Jeffrey E Lancet; Maurizio Zangari; Paul J Shami; Khuda Dad Khan; Alison L Hannah; Julie M Cherrington; Deborah A Thomas; Guillermo Garcia-Manero; Maher Albitar; Hagop M Kantarjian; Alison T Stopeck
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2002: Alison T Stopeck; Marrae Sheldon; Mahmood Vahedian; Gillian Cropp; Rishi Gosalia; Alison L Hannah
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2798-805.
2002: Julia A Coronella; Catherine Spier; Matthew Welch; Katrina T Trevor; Alison T Stopeck; Hugo V Villar; Evan M Hersh
Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(4):1829-36.
2002: Maria I Altbach; Eric K Outwater; Theodore P Trouard; Elizabeth Krupinski; Rebecca J Theilmann; Alison T Stopeck; Mitsuko Kono; Arthur F Gmitro
Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liver.
Journal of magnetic resonance imaging : JMRI 2002;16(2):179-89.
2001: Alison T Stopeck; A Jones; Evan M Hersh; J A Thompson; D M Finucane; J C Gutheil; R Gonzalez
Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2285-91.
2000: Alison T Stopeck; A Gessner; Thomas P Miller; Evan M Hersh; C S Johnson; Haiyan Cui; Yvette M Frutiger; Thomas M Grogan
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):3904-9.
2000: PR Clark; Alison T Stopeck; SE Parker; Evan M Hersh
Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.
Cellular immunology 2000;204(2):96-104.
2000: PR Clark; Alison T Stopeck; M Ferrari; SE Parker; Evan M Hersh
Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.
Cancer gene therapy 2000;7(6):853-60.
2000: Tom C Tsang; Jacqueline L Brailey; Farha H Vasanwala; Rita S Wu; F Liu; PR Clark; Linda C Meade-Tollin; L Luznick; Alison T Stopeck; Emmanuel T Akporiaye; David T Harris
Construction of new amplifier expression vectors for high levels of IL-2 gene expression.
International journal of molecular medicine 2000;5(3):295-300.
1999: Evanthia C Galanis; Evan M Hersh; Alison T Stopeck; R Gonzalez; Patrick A Burch; Catherine Spier; Emmanuel T Akporiaye; J J Rinehart; John H Edmonson; R E Sobol; C Forscher; vernon sondak; Bradley D Lewis; E C Unger; M O'Driscoll; L Selk; Joseph Rubin
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3313-23.
1999: PR Clark; Alison T Stopeck; Jacqueline L Brailey; Q Wang; J McArthur; MH Finer; Evan M Hersh
Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells.
Cancer gene therapy 1999;6(5):437-46.
1998: Alison T Stopeck; Evan M Hersh; Jacqueline L Brailey; PR Clark; J Norman; SE Parker
Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes.
Cancer gene therapy 1998;5(2):119-26.
1997: Evan M Hersh; Alison T Stopeck
Advances in the biological therapy and gene therapy of malignant disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2623-9.
1997: Evan M Hersh; Alison T Stopeck
Recent advances in the treatment of malignant melanoma with gene therapy.
Molecular medicine (Cambridge, Mass.) 1997;3(10):636-51.
1997: LS Snyder; Alison T Stopeck; J H Godwin
HIV/AIDS case histories: diagnostic problems. Pulmonary coccidioidomycosis.
AIDS patient care and STDs 1997;11(4):285-6.
1997: W Waddill; W Wright; E Unger; Alison T Stopeck; Emmanuel T Akporiaye; D Harris; Thomas M Grogan; Samuel F Schluter; Evan M Hersh; S Stahl
Human gene therapy for melanoma: CT-guided interstitial injection.
AJR. American journal of roentgenology 1997;169(1):63-7.
1997: Alison T Stopeck; M Vahedian; S K Williams
Transfer and expression of the interferon gamma gene in human endothelial cells inhibits vascular smooth muscle cell growth in vitro.
Cell transplantation 1997;6(1):1-8.
1997: Alison T Stopeck; Evan M Hersh; Emmanuel T Akporiaye; David T Harris; Thomas M Grogan; E Unger; James Warneke; Samuel F Schluter; S Stahl
Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):341-9.
1996: SE Parker; S Khatibi; Michal Margalith; D Anderson; M Yankauckas; S H Gromkowski; T Latimer; D Lew; M Marquet; Marston Manthorpe; Peter Hobart; Evan M Hersh; Alison T Stopeck; Jon Norman
Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Cancer gene therapy 1996;3(3):175-85.
1996: M C Panelli; E Wang; S Shen; Samuel F Schluter; R M Bernstein; Evan M Hersh; Alison T Stopeck; R Gangavalli; J Barber; D Jolly; Emmanuel T Akporiaye
Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC.
Cancer immunology, immunotherapy : CII 1996;42(2):99-107.
1994: Evan M Hersh; Emmanuel T Akporiaye; D Harris; Alison T Stopeck; E C Unger; James Warneke; S A Kradjian
Phase I study of immunotherapy of malignant melanoma by direct gene transfer.
Human gene therapy 1994;5(11):1371-84.
1991: JH Godwin; Alison T Stopeck; V T Chang; TA Godwin
Mycobacteremia in acquired immune deficiency syndrome. Rapid diagnosis based on inclusions in the peripheral blood smear.
American journal of clinical pathology 1991;95(3):369-75.